<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436565</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11721</org_study_id>
    <secondary_id>U1111-1121-4146</secondary_id>
    <nct_id>NCT01436565</nct_id>
  </id_info>
  <brief_title>A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers</brief_title>
  <official_title>A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of&#xD;
           SAR245408 administered in combination with SAR256212 in adult patients with locally&#xD;
           advanced or metastatic solid tumors.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To characterize the global safety profile of SAR245408 in combination with SAR256212&#xD;
&#xD;
        -  To evaluate the pharmacokinetic (PK) profile of SAR245408 and SAR256212 used in&#xD;
           combination&#xD;
&#xD;
        -  To evaluate the objective response rate (ORR) and tumor volume change (for expansion&#xD;
           cohort only)&#xD;
&#xD;
        -  To determine the immunogenicity of SAR256212 as administered with SAR245408&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a 28 day screening period followed by 28 day cycles (21 day cycle for the every&#xD;
      three week dosing regimen, if used) . Patients will continue to receive SAR245408/SAR256212&#xD;
      as long as there is clinical benefit or until a study withdrawal criterion is met. The last&#xD;
      posttreatment visit will be 60 days after the last dose or until IMP-related toxicities have&#xD;
      resolved or are deemed irreversible, whichever is later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>2 months to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak and trough levels of SAR256212 and SAR245408</measure>
    <time_frame>1 month to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic change in ErbB3 protein and mRNA levels as well as components of the PI3K pathway will be measured</measure>
    <time_frame>1 month to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 month to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 months to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who develop anti-MM-121 antibodies</measure>
    <time_frame>1 month to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Solid Tumor Cancers</condition>
  <arm_group>
    <arm_group_label>dose escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-121 (SAR256212)</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: Intravenous</description>
    <arm_group_label>dose escalation and expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR245408</intervention_name>
    <description>Pharmaceutical form:tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>dose escalation and expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Metastatic or locally advanced nonhematological cancer, for which no alternative&#xD;
             therapy is available&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  For dose expansion only:&#xD;
&#xD;
               -  Patient's tumor harbors activating mutations in phosphoinositide-3-kinase,&#xD;
                  catalytic, alpha polypeptide (PIK3CA)&#xD;
&#xD;
               -  Tissue from archived sample&#xD;
&#xD;
          -  Measurable and evaluable disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient less than 18 years old&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) performance status &gt;2&#xD;
&#xD;
          -  Any serious active disease or comorbid condition, which, in the opinion of the&#xD;
             Investigator, could interfere with the safety of the patient or the ability of the&#xD;
             patient to comply with the study, or with the interpretation of the results&#xD;
&#xD;
          -  Poor bone marrow reserve as defined by absolute neutrophils count &lt;1.5 x 109/L or&#xD;
             platelets &lt;100 x 109/L&#xD;
&#xD;
          -  Poor organ function as defined by 1 of the following:&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  AST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) &gt;2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &gt;1.5 x ULN and/or creatinine clearance &lt;60 mL/min&#xD;
&#xD;
               -  PT/ (INR) (prothrombin time) (International Normalized Ratio) and/or partial&#xD;
                  thromboplastin time (PTT) test results ≥1.3 ULN&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  No use of effective birth control methods, when applicable&#xD;
&#xD;
          -  No resolution of all specific toxicities (excluding alopecia) related to any prior&#xD;
             anticancer therapy to Grade ≤1 according to the NCI common terminology criteria for&#xD;
             adverse events (CTCAE) v.4.0&#xD;
&#xD;
          -  Any of the following within 6 months prior to enrollment: myocardial infarction,&#xD;
             severe/unstable angina, or coronary/peripheral artery bypass graft surgery, clinically&#xD;
             symptomatic and uncontrolled cardiovascular disease, or clinically significant cardiac&#xD;
             arrhythmias (Grade 3/4)&#xD;
&#xD;
          -  Baseline corrected QT interval (QTc) &gt;460 ms.&#xD;
&#xD;
          -  NYHA Class III (New York Heart Association) or IV congestive heart failure or LVEF&#xD;
             (left ventricular ejection fraction) &lt; the lower limit of normal (LLN) for institution&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection (including cytomegalovirus, Epstein-Barr virus, toxoplasmosis, and hepatitis&#xD;
             B and C, positive for the human immunodeficiency virus (HIV), hypertension, or&#xD;
             uncontrolled diabetes.&#xD;
&#xD;
          -  Previous treatment with a selective PI3K inhibitor (phosphoinositide-3-kinase,&#xD;
             catalytic, alpha polypeptide), mTOR (mechanistic target of rapamycin) inhibitor, or&#xD;
             AKT inhibitor (v-akt murine thymoma viral oncogene homolog 1)&#xD;
&#xD;
          -  Known hypersensitivity to the investigational medicinal product(s) or to its&#xD;
             excipients, or patient who has had hypersensitivity reactions to fully human&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  Cytotoxic chemotherapy (including investigational cytotoxic agents) or biologic agents&#xD;
             (antibodies, immune modulators, cytokines) within 4 weeks, or nitrosoureas or&#xD;
             mitomycin C within 6 weeks, before the first dose of study treatment&#xD;
&#xD;
          -  Prior radiation therapy within 2 weeks before the first dose of study treatment&#xD;
&#xD;
          -  Prior major surgery from which the patient has not recovered or stabilized&#xD;
&#xD;
          -  Any other investigational therapy within 4 weeks prior to the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Brain tumor or brain metastasis are considered eligible if the patient has not&#xD;
             received radiation therapy for brain metastasis within 2 weeks of enrollment and has&#xD;
             been on a stable dose of steroids for 2 or more weeks&#xD;
&#xD;
          -  Ongoing anticoagulation with therapeutic doses of warfarin (low-dose warfarin ≤1&#xD;
             mg/day is permitted).&#xD;
&#xD;
          -  HBA1C (hemoglobin A1c) &gt;7 or any patient requiring medication for glycemic control&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840101</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

